Illumina (NASDAQ:ILMN) had its price target boosted by investment analysts at Cowen from $250.00 to $275.00 in a report issued on Monday. The brokerage presently has an “outperform” rating on the life sciences company’s stock. Cowen’s price objective suggests a potential upside of 12.16% from the stock’s current price.
A number of other research analysts have also commented on the company. BTIG Research reiterated a “hold” rating on shares of Illumina in a research report on Tuesday, January 16th. Deutsche Bank set a $275.00 price target on Illumina and gave the company a “buy” rating in a research note on Tuesday, January 16th. Wells Fargo & Co reissued a “positive” rating and issued a $260.00 price target (up previously from $250.00) on shares of Illumina in a research note on Tuesday, January 9th. Piper Jaffray Companies reissued a “buy” rating and issued a $269.00 price target on shares of Illumina in a research note on Tuesday, January 9th. Finally, William Blair downgraded Illumina from an “outperform” rating to a “market perform” rating in a research note on Friday, January 5th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $223.88.
Shares of Illumina (NASDAQ:ILMN) traded up $1.64 on Monday, reaching $245.19. The company’s stock had a trading volume of 709,832 shares, compared to its average volume of 872,884. The company has a market cap of $35,800.00, a price-to-earnings ratio of 46.26, a price-to-earnings-growth ratio of 3.27 and a beta of 0.79. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.22 and a quick ratio of 3.73. Illumina has a 52-week low of $156.50 and a 52-week high of $248.97.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. During the same period last year, the company earned $0.97 EPS. equities analysts forecast that Illumina will post 3.77 earnings per share for the current fiscal year.
In related news, SVP Charles Dadswell sold 145 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $225.33, for a total transaction of $32,672.85. Following the sale, the senior vice president now owns 6,388 shares of the company’s stock, valued at approximately $1,439,408.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Marc Stapley sold 2,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $205.48, for a total value of $410,960.00. Following the sale, the executive vice president now directly owns 30,370 shares in the company, valued at approximately $6,240,427.60. The disclosure for this sale can be found here. Insiders have sold a total of 154,671 shares of company stock worth $33,626,228 in the last ninety days. 0.89% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of ILMN. Winslow Capital Management LLC acquired a new stake in Illumina during the 2nd quarter worth $211,584,000. Fred Alger Management Inc. raised its stake in Illumina by 611.9% during the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock worth $110,636,000 after buying an additional 548,030 shares during the period. Capital World Investors raised its stake in Illumina by 23.8% during the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock worth $370,465,000 after buying an additional 410,000 shares during the period. Janus Henderson Group PLC raised its stake in Illumina by 1,556.2% during the 2nd quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock worth $57,263,000 after buying an additional 310,084 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Illumina during the 2nd quarter worth $47,010,000. 91.63% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Illumina (ILMN) Given New $275.00 Price Target at Cowen” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/22/illumina-ilmn-given-new-275-00-price-target-at-cowen.html.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.